<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123916</url>
  </required_header>
  <id_info>
    <org_study_id>BEN01</org_study_id>
    <secondary_id>CONEP-11394</secondary_id>
    <nct_id>NCT00123916</nct_id>
  </id_info>
  <brief_title>BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease</brief_title>
  <acronym>BENEFIT</acronym>
  <official_title>Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Dante Pazzanese de Cardiologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for
      60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment -
      period adjusted according to the patient's body weight to a total minimum dose of 12g
      (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces
      morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC).

      The BENEFIT study is being conducted by the Population Health Research Institute (in
      Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil)
      together with an independent Steering Committee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double-blind controlled clinical trial investigating the role of benznidazole in
      patients with chronic Chagas' heart disease.

      Chagas disease has 3 phases: acute, undetermined and chronic phases. There are no clinical
      trials up to date that have investigated the use of antiparasitic drugs in patients that are
      in the chronic phase.

      This study will evaluate the efficacy and safety of benznidazole (an antiparasitic drug) in
      patients with chronic Chagas' heart disease. Evaluate if benznidazole, an antiparasite drug,
      given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose
      of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body
      weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g
      (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas'
      Cardiomyopathy (CCC). It will be developed in 54 study centres in Argentina,
      Bolivia,Brazil,Colombia and El Salvador - countries with high incidence of Chagas Disease.

      The Pilot study is evaluating if benznidazole is effective in producing parasitic cure (PCR
      negativization or reducing parasitic load) in chronic Chagas Disease as well as assessing the
      feasibility of conducting a large trial in chronic Chagas Disease in South America.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>It will also evaluate the cardiovascular events of the large outcome trial, the first occurrence of any of the following clinically significant outcomes: Death</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Resuscitated cardiac arrest, requiring defibrillator or cardioversion</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac arrest secondary to bradyarrythmias, ventricular tachycardia, ventricular flutter, or ventricular fibrillation that requires CPR and or electrical cardioversion or defibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Documented sustained ventricular tachycardia requiring cardioversion</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>New development of symptomatic congestive heart failure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pacemaker or implantable cardiac defibrillator implantation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke or any other thromboembolic event in patients with no prior thromboembolic phenomena</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Transplant</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New development of any of the following echo changes clinically indicated or done for the trial: Segmental wall motion abnormalities</measure>
    <time_frame>2 year and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular aneurysm</measure>
    <time_frame>2 year and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in left ventricular (LV) ejection fraction &gt; 5%</measure>
    <time_frame>2 year and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in left ventricular diastolic dysfunction (LVDD) &gt; 5.0 mm compared with baseline</measure>
    <time_frame>2 year and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.)</measure>
    <time_frame>2 year and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of New York Heart Association (NYHA) functional class by at least one category</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of benznidazole</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chagas Disease</condition>
  <condition>Trypanosomiasis</condition>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 days treatment with benznidazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 days treatment with matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>Daily po Benznidazole or placebo (weight based) during 60 days,</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rochagan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rochagan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting patients (between 18 and 75 years of age) with serological evidence of
             Chagas infection (any combination of 2 positive tests) and that have one or more of
             the following:

          -  Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left
             anterior or posterior fascicular block; ventricular premature beat; first degree
             atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T
             changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);

          -  Abnormal ECG (Mobitz type II, advanced or third degree AV block);

          -  Increased cardiothoracic ratio (&gt; 0.50);

          -  Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;

          -  Evidence of regional wall motion abnormality or reduced global left ventricular
             systolic function or increased left ventricular and diastolic diameter on 2D-Echo.

        Exclusion Criteria:

        Patients will be excluded if having:

          -  NYHA heart failure class IV or decompensated heart failure

          -  Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated
             cardiomyopathy

          -  Previous treatment with antitrypanosomal agents or an accepted indication for
             antiparasitic therapy

          -  Inability to comply with follow-up visits

          -  History of severe alcohol abuse within 2 years

          -  Known chronic renal or hepatic insufficiency or hepatic insufficiency

          -  Pregnancy or breast feeding

          -  Megaesophagus with swallowing impairment

          -  Other severe disease significantly curtailing life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Morillo, MD, FRCPC, FAC</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute - McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Antonio Marin-Neto, MD, PhD,FACC</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salim Yusuf, MD, DPh, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute - McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Sosa-Estani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Argentina National Coordinator - CenDIE, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Rosas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Clinica Shaio, Bogota, Colombia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos A. Morillo, MD</last_name>
    <phone>1-905-527-4322</phone>
    <phone_ext>40311</phone_ext>
    <email>benefit@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alvaro Avezum, MD,PhD</last_name>
    <phone>55-11-5085-6204</phone>
    <email>benefit@dantepazzanese.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BENEFIT Ivestigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>apital Federal</state>
        <zip>3556</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Escobar</city>
        <state>Buenos Aires</state>
        <zip>1753</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Isidro Casanova</city>
        <state>Buenos Aires</state>
        <zip>1282</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Juan</city>
        <state>Buenos Aires</state>
        <zip>1625</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <state>Buenos Aires</state>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <state>Buenos Aires</state>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>1063</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Fernando del Valle de Catamarca</city>
        <state>Catamarca</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Charata</city>
        <state>Chaco</state>
        <zip>H3730AVI</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Paraná</city>
        <state>Entre Rios</state>
        <zip>3100</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <state>General Rodríguez Partido</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <state>Jujuy</state>
        <zip>4600</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Corrientes</city>
        <state>Rosario, Santa Fe</state>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Añatuya</city>
        <state>Santiago del Estero</state>
        <zip>3760</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Santiago Del Estero</city>
        <state>Sgo. Del Estero</state>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salta</city>
        <zip>A4406CLA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Tupiza</city>
        <state>Potosi</state>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Recife</city>
        <state>- Pernambuco</state>
        <zip>50100-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahaia</state>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahaia</state>
        <zip>40110-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahaia</state>
        <zip>40425-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Carmo</city>
        <state>Belo Horizonte</state>
        <zip>30130-690</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Brasília</city>
        <state>Brazilian Federal District</state>
        <zip>70658-700</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74605-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Uberlandia</city>
        <state>MG</state>
        <zip>38025-440</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Uberlândia</city>
        <state>MG</state>
        <zip>38400-299</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Uberaba</city>
        <state>Minas Gerais</state>
        <zip>38010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Pelotas</city>
        <state>Rio Grande do Sul</state>
        <zip>96015-290</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13059-740</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15015-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <zip>15500-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01417 010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Bogotá</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Gil</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BENEFIT Ivestigational Site</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bolivia</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>El Salvador</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.phri.ca</url>
    <description>Population Health Research Institute</description>
  </link>
  <link>
    <url>http://www.dantepazzanese.org.br/pesquisa</url>
    <description>Instituto Dante Pazzanese de Cardiologia</description>
  </link>
  <verification_date>June 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2005</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dante Pazzanese, Instituto de Pesquisa</name_title>
    <organization>Dante Pazzanese</organization>
  </responsible_party>
  <keyword>Chagas Disease</keyword>
  <keyword>Trypanosomiasis</keyword>
  <keyword>Benznidazole</keyword>
  <keyword>Chronic Heart disease</keyword>
  <keyword>Trypanosoma Cruzi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Chagas Disease</mesh_term>
    <mesh_term>Trypanosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

